Nanotechnology-Enabled Topical Drug Delivery for Trigeminal Neuralgia: Current Status and Future Directions
Trigeminal neuralgia (TN) is a severely incapacitating condition marked by recurring bouts of intense, short-lived, electric shock-like face pain. In order to better characterize patients and aid in the decision-making process regarding medicinal and surgical therapies, new diagnostic criteria that subclassify TN based on the existence of trigeminal neurovascular conflict or an underlying neurological condition should be implemented. The diagnostic work-up should include MR imaging, especially high-resolution trigeminal sequences. The preferred medications are oxcarbazepine and carbamazepine. Botulinum toxin type A, baclofen, gabapentin, pregabalin, and lamotrigine can be taken either on their own or in combination with other medications. If the medicinal therapies are not well accepted or the pain is not well managed, surgery should be considered. For patients with trigeminal neurovascular conflict, trigeminal microvascular decompression is the first-line surgical procedure. If MR imaging reveals no neurovascular contact, or if patients are deemed too weak for microvascular decompression or do not want to take the risk, neuroablative surgical treatments may be available.
Authors
- Neha Patil
- S.P. Pawar
- Mrunal D. Pendharkar
- Sanket Patil
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24333842
- Primary Topic
- Trigeminal Neuralgia and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00